Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?

Journal article

Open access

Peer reviewed

Bradley J. Monk, Warner K. Huh, Julie Ann Rosenberg and Ira Jacobs

Gynecologic oncology research and practice, Vol.4(1), pp.7-7

03/21/2017

PMCID: PMC5361700

PMID: 28344818

Abstract

Bevacizumab

Biosimilar

Cervical cancer

Ovarian cancer

Review

url

https://doi.org/10.1186/s40661-017-0045-xView

Published (Version of record) Open

4 Record Views

Title: Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
Creators: Bradley J. Monk - Creighton University
Warner K. Huh - University of Alabama at Birmingham
Julie Ann Rosenberg - Pfizer
Ira Jacobs - Pfizer
Publication Details: Gynecologic oncology research and practice, Vol.4(1), pp.7-7
Publisher: BioMed Central
Grant note: N/A / ;
Identifiers: 991005969068002656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article